

Global Short-acting B2 Agonists Market Growth 2023-2029

<https://marketpublishers.com/r/G8157D4BB48DEN.html>

Date: March 2023

Pages: 99

Price: US\$ 3,660.00 (Single User License)

ID: G8157D4BB48DEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Short-acting B2 Agonists market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Short-acting B2 Agonists is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Short-acting B2 Agonists is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Short-acting B2 Agonists is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Short-acting B2 Agonists players cover Bayer AG, Teva, Roche, Viatris, GSK, Cipla Limited, Johnson & Johnson and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Short-acting B2 agonists (SABAs) are albuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm caused by COPD, bronchial asthma, or emphysema.

LPI (LP Information)' newest research report, the "Short-acting B2 Agonists Industry Forecast" looks at past sales and reviews total world Short-acting B2 Agonists sales in 2022, providing a comprehensive analysis by region and market sector of projected Short-acting B2 Agonists sales for 2023 through 2029. With Short-acting B2 Agonists

sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Short-acting B2 Agonists industry.

This Insight Report provides a comprehensive analysis of the global Short-acting B2 Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short-acting B2 Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Short-acting B2 Agonists market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short-acting B2 Agonists and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short-acting B2 Agonists.

This report presents a comprehensive overview, market shares, and growth opportunities of Short-acting B2 Agonists market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Albuterol

Metaproterenol

Levalbuterol

Other

Segmentation by application

COPD

Asthma

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Bayer AG

Teva

Roche

Viartis

GSK

Cipla Limited

Johnson & Johnson

Merck

Key Questions Addressed in this Report

Global Short-acting B2 Agonists Market Growth 2023-2029

What is the 10-year outlook for the global Short-acting B2 Agonists market?

What factors are driving Short-acting B2 Agonists market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Short-acting B2 Agonists market opportunities vary by end market size?

How does Short-acting B2 Agonists break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Short-acting B2 Agonists Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Short-acting B2 Agonists by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Short-acting B2 Agonists by Country/Region, 2018, 2022 & 2029
- 2.2 Short-acting B2 Agonists Segment by Type
 - 2.2.1 Albuterol
 - 2.2.2 Metaproterenol
 - 2.2.3 Levalbuterol
 - 2.2.4 Other
- 2.3 Short-acting B2 Agonists Sales by Type
 - 2.3.1 Global Short-acting B2 Agonists Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Short-acting B2 Agonists Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Short-acting B2 Agonists Sale Price by Type (2018-2023)
- 2.4 Short-acting B2 Agonists Segment by Application
 - 2.4.1 COPD
 - 2.4.2 Asthma
 - 2.4.3 Other
- 2.5 Short-acting B2 Agonists Sales by Application
 - 2.5.1 Global Short-acting B2 Agonists Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Short-acting B2 Agonists Revenue and Market Share by Application (2018-2023)

2.5.3 Global Short-acting B2 Agonists Sale Price by Application (2018-2023)

3 GLOBAL SHORT-ACTING B2 AGONISTS BY COMPANY

3.1 Global Short-acting B2 Agonists Breakdown Data by Company

3.1.1 Global Short-acting B2 Agonists Annual Sales by Company (2018-2023)

3.1.2 Global Short-acting B2 Agonists Sales Market Share by Company (2018-2023)

3.2 Global Short-acting B2 Agonists Annual Revenue by Company (2018-2023)

3.2.1 Global Short-acting B2 Agonists Revenue by Company (2018-2023)

3.2.2 Global Short-acting B2 Agonists Revenue Market Share by Company (2018-2023)

3.3 Global Short-acting B2 Agonists Sale Price by Company

3.4 Key Manufacturers Short-acting B2 Agonists Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Short-acting B2 Agonists Product Location Distribution

3.4.2 Players Short-acting B2 Agonists Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR SHORT-ACTING B2 AGONISTS BY GEOGRAPHIC REGION

4.1 World Historic Short-acting B2 Agonists Market Size by Geographic Region (2018-2023)

4.1.1 Global Short-acting B2 Agonists Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Short-acting B2 Agonists Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Short-acting B2 Agonists Market Size by Country/Region (2018-2023)

4.2.1 Global Short-acting B2 Agonists Annual Sales by Country/Region (2018-2023)

4.2.2 Global Short-acting B2 Agonists Annual Revenue by Country/Region (2018-2023)

4.3 Americas Short-acting B2 Agonists Sales Growth

4.4 APAC Short-acting B2 Agonists Sales Growth

4.5 Europe Short-acting B2 Agonists Sales Growth

4.6 Middle East & Africa Short-acting B2 Agonists Sales Growth

5 AMERICAS

5.1 Americas Short-acting B2 Agonists Sales by Country

5.1.1 Americas Short-acting B2 Agonists Sales by Country (2018-2023)

5.1.2 Americas Short-acting B2 Agonists Revenue by Country (2018-2023)

5.2 Americas Short-acting B2 Agonists Sales by Type

5.3 Americas Short-acting B2 Agonists Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Short-acting B2 Agonists Sales by Region

6.1.1 APAC Short-acting B2 Agonists Sales by Region (2018-2023)

6.1.2 APAC Short-acting B2 Agonists Revenue by Region (2018-2023)

6.2 APAC Short-acting B2 Agonists Sales by Type

6.3 APAC Short-acting B2 Agonists Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Short-acting B2 Agonists by Country

7.1.1 Europe Short-acting B2 Agonists Sales by Country (2018-2023)

7.1.2 Europe Short-acting B2 Agonists Revenue by Country (2018-2023)

7.2 Europe Short-acting B2 Agonists Sales by Type

7.3 Europe Short-acting B2 Agonists Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Short-acting B2 Agonists by Country

8.1.1 Middle East & Africa Short-acting B2 Agonists Sales by Country (2018-2023)

8.1.2 Middle East & Africa Short-acting B2 Agonists Revenue by Country (2018-2023)

8.2 Middle East & Africa Short-acting B2 Agonists Sales by Type

8.3 Middle East & Africa Short-acting B2 Agonists Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Short-acting B2 Agonists

10.3 Manufacturing Process Analysis of Short-acting B2 Agonists

10.4 Industry Chain Structure of Short-acting B2 Agonists

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Short-acting B2 Agonists Distributors

11.3 Short-acting B2 Agonists Customer

12 WORLD FORECAST REVIEW FOR SHORT-ACTING B2 AGONISTS BY GEOGRAPHIC REGION

- 12.1 Global Short-acting B2 Agonists Market Size Forecast by Region
 - 12.1.1 Global Short-acting B2 Agonists Forecast by Region (2024-2029)
 - 12.1.2 Global Short-acting B2 Agonists Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Short-acting B2 Agonists Forecast by Type
- 12.7 Global Short-acting B2 Agonists Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Bayer AG
 - 13.1.1 Bayer AG Company Information
 - 13.1.2 Bayer AG Short-acting B2 Agonists Product Portfolios and Specifications
 - 13.1.3 Bayer AG Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Bayer AG Main Business Overview
 - 13.1.5 Bayer AG Latest Developments
- 13.2 Teva
 - 13.2.1 Teva Company Information
 - 13.2.2 Teva Short-acting B2 Agonists Product Portfolios and Specifications
 - 13.2.3 Teva Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Teva Main Business Overview
 - 13.2.5 Teva Latest Developments
- 13.3 Roche
 - 13.3.1 Roche Company Information
 - 13.3.2 Roche Short-acting B2 Agonists Product Portfolios and Specifications
 - 13.3.3 Roche Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Roche Main Business Overview
 - 13.3.5 Roche Latest Developments
- 13.4 Viatris
 - 13.4.1 Viatris Company Information
 - 13.4.2 Viatris Short-acting B2 Agonists Product Portfolios and Specifications
 - 13.4.3 Viatris Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin

(2018-2023)

13.4.4 Viatris Main Business Overview

13.4.5 Viatris Latest Developments

13.5 GSK

13.5.1 GSK Company Information

13.5.2 GSK Short-acting B2 Agonists Product Portfolios and Specifications

13.5.3 GSK Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin

(2018-2023)

13.5.4 GSK Main Business Overview

13.5.5 GSK Latest Developments

13.6 Cipla Limited

13.6.1 Cipla Limited Company Information

13.6.2 Cipla Limited Short-acting B2 Agonists Product Portfolios and Specifications

13.6.3 Cipla Limited Short-acting B2 Agonists Sales, Revenue, Price and Gross

Margin (2018-2023)

13.6.4 Cipla Limited Main Business Overview

13.6.5 Cipla Limited Latest Developments

13.7 Johnson & Johnson

13.7.1 Johnson & Johnson Company Information

13.7.2 Johnson & Johnson Short-acting B2 Agonists Product Portfolios and Specifications

13.7.3 Johnson & Johnson Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Johnson & Johnson Main Business Overview

13.7.5 Johnson & Johnson Latest Developments

13.8 Merck

13.8.1 Merck Company Information

13.8.2 Merck Short-acting B2 Agonists Product Portfolios and Specifications

13.8.3 Merck Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin

(2018-2023)

13.8.4 Merck Main Business Overview

13.8.5 Merck Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Short-acting B2 Agonists Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Short-acting B2 Agonists Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Albuterol

Table 4. Major Players of Metaproterenol

Table 5. Major Players of Levalbuterol

Table 6. Major Players of Other

Table 7. Global Short-acting B2 Agonists Sales by Type (2018-2023) & (K Units)

Table 8. Global Short-acting B2 Agonists Sales Market Share by Type (2018-2023)

Table 9. Global Short-acting B2 Agonists Revenue by Type (2018-2023) & (\$ million)

Table 10. Global Short-acting B2 Agonists Revenue Market Share by Type (2018-2023)

Table 11. Global Short-acting B2 Agonists Sale Price by Type (2018-2023) & (US\$/Unit)

Table 12. Global Short-acting B2 Agonists Sales by Application (2018-2023) & (K Units)

Table 13. Global Short-acting B2 Agonists Sales Market Share by Application (2018-2023)

Table 14. Global Short-acting B2 Agonists Revenue by Application (2018-2023)

Table 15. Global Short-acting B2 Agonists Revenue Market Share by Application (2018-2023)

Table 16. Global Short-acting B2 Agonists Sale Price by Application (2018-2023) & (US\$/Unit)

Table 17. Global Short-acting B2 Agonists Sales by Company (2018-2023) & (K Units)

Table 18. Global Short-acting B2 Agonists Sales Market Share by Company (2018-2023)

Table 19. Global Short-acting B2 Agonists Revenue by Company (2018-2023) (\$ Millions)

Table 20. Global Short-acting B2 Agonists Revenue Market Share by Company (2018-2023)

Table 21. Global Short-acting B2 Agonists Sale Price by Company (2018-2023) & (US\$/Unit)

Table 22. Key Manufacturers Short-acting B2 Agonists Producing Area Distribution and Sales Area

Table 23. Players Short-acting B2 Agonists Products Offered

Table 24. Short-acting B2 Agonists Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Short-acting B2 Agonists Sales by Geographic Region (2018-2023) & (K Units)

Table 28. Global Short-acting B2 Agonists Sales Market Share Geographic Region (2018-2023)

Table 29. Global Short-acting B2 Agonists Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 30. Global Short-acting B2 Agonists Revenue Market Share by Geographic Region (2018-2023)

Table 31. Global Short-acting B2 Agonists Sales by Country/Region (2018-2023) & (K Units)

Table 32. Global Short-acting B2 Agonists Sales Market Share by Country/Region (2018-2023)

Table 33. Global Short-acting B2 Agonists Revenue by Country/Region (2018-2023) & (\$ millions)

Table 34. Global Short-acting B2 Agonists Revenue Market Share by Country/Region (2018-2023)

Table 35. Americas Short-acting B2 Agonists Sales by Country (2018-2023) & (K Units)

Table 36. Americas Short-acting B2 Agonists Sales Market Share by Country (2018-2023)

Table 37. Americas Short-acting B2 Agonists Revenue by Country (2018-2023) & (\$ Millions)

Table 38. Americas Short-acting B2 Agonists Revenue Market Share by Country (2018-2023)

Table 39. Americas Short-acting B2 Agonists Sales by Type (2018-2023) & (K Units)

Table 40. Americas Short-acting B2 Agonists Sales by Application (2018-2023) & (K Units)

Table 41. APAC Short-acting B2 Agonists Sales by Region (2018-2023) & (K Units)

Table 42. APAC Short-acting B2 Agonists Sales Market Share by Region (2018-2023)

Table 43. APAC Short-acting B2 Agonists Revenue by Region (2018-2023) & (\$ Millions)

Table 44. APAC Short-acting B2 Agonists Revenue Market Share by Region (2018-2023)

Table 45. APAC Short-acting B2 Agonists Sales by Type (2018-2023) & (K Units)

Table 46. APAC Short-acting B2 Agonists Sales by Application (2018-2023) & (K Units)

Table 47. Europe Short-acting B2 Agonists Sales by Country (2018-2023) & (K Units)

Table 48. Europe Short-acting B2 Agonists Sales Market Share by Country (2018-2023)

Table 49. Europe Short-acting B2 Agonists Revenue by Country (2018-2023) & (\$

Millions)

Table 50. Europe Short-acting B2 Agonists Revenue Market Share by Country (2018-2023)

Table 51. Europe Short-acting B2 Agonists Sales by Type (2018-2023) & (K Units)

Table 52. Europe Short-acting B2 Agonists Sales by Application (2018-2023) & (K Units)

Table 53. Middle East & Africa Short-acting B2 Agonists Sales by Country (2018-2023) & (K Units)

Table 54. Middle East & Africa Short-acting B2 Agonists Sales Market Share by Country (2018-2023)

Table 55. Middle East & Africa Short-acting B2 Agonists Revenue by Country (2018-2023) & (\$ Millions)

Table 56. Middle East & Africa Short-acting B2 Agonists Revenue Market Share by Country (2018-2023)

Table 57. Middle East & Africa Short-acting B2 Agonists Sales by Type (2018-2023) & (K Units)

Table 58. Middle East & Africa Short-acting B2 Agonists Sales by Application (2018-2023) & (K Units)

Table 59. Key Market Drivers & Growth Opportunities of Short-acting B2 Agonists

Table 60. Key Market Challenges & Risks of Short-acting B2 Agonists

Table 61. Key Industry Trends of Short-acting B2 Agonists

Table 62. Short-acting B2 Agonists Raw Material

Table 63. Key Suppliers of Raw Materials

Table 64. Short-acting B2 Agonists Distributors List

Table 65. Short-acting B2 Agonists Customer List

Table 66. Global Short-acting B2 Agonists Sales Forecast by Region (2024-2029) & (K Units)

Table 67. Global Short-acting B2 Agonists Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 68. Americas Short-acting B2 Agonists Sales Forecast by Country (2024-2029) & (K Units)

Table 69. Americas Short-acting B2 Agonists Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 70. APAC Short-acting B2 Agonists Sales Forecast by Region (2024-2029) & (K Units)

Table 71. APAC Short-acting B2 Agonists Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 72. Europe Short-acting B2 Agonists Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Europe Short-acting B2 Agonists Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Middle East & Africa Short-acting B2 Agonists Sales Forecast by Country (2024-2029) & (K Units)

Table 75. Middle East & Africa Short-acting B2 Agonists Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 76. Global Short-acting B2 Agonists Sales Forecast by Type (2024-2029) & (K Units)

Table 77. Global Short-acting B2 Agonists Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 78. Global Short-acting B2 Agonists Sales Forecast by Application (2024-2029) & (K Units)

Table 79. Global Short-acting B2 Agonists Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 80. Bayer AG Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 81. Bayer AG Short-acting B2 Agonists Product Portfolios and Specifications

Table 82. Bayer AG Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 83. Bayer AG Main Business

Table 84. Bayer AG Latest Developments

Table 85. Teva Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 86. Teva Short-acting B2 Agonists Product Portfolios and Specifications

Table 87. Teva Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 88. Teva Main Business

Table 89. Teva Latest Developments

Table 90. Roche Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 91. Roche Short-acting B2 Agonists Product Portfolios and Specifications

Table 92. Roche Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 93. Roche Main Business

Table 94. Roche Latest Developments

Table 95. Viartis Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 96. Viartis Short-acting B2 Agonists Product Portfolios and Specifications

Table 97. Viartis Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price

(US\$/Unit) and Gross Margin (2018-2023)

Table 98. Viatris Main Business

Table 99. Viatris Latest Developments

Table 100. GSK Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 101. GSK Short-acting B2 Agonists Product Portfolios and Specifications

Table 102. GSK Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 103. GSK Main Business

Table 104. GSK Latest Developments

Table 105. Cipla Limited Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 106. Cipla Limited Short-acting B2 Agonists Product Portfolios and Specifications

Table 107. Cipla Limited Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 108. Cipla Limited Main Business

Table 109. Cipla Limited Latest Developments

Table 110. Johnson & Johnson Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 111. Johnson & Johnson Short-acting B2 Agonists Product Portfolios and Specifications

Table 112. Johnson & Johnson Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 113. Johnson & Johnson Main Business

Table 114. Johnson & Johnson Latest Developments

Table 115. Merck Basic Information, Short-acting B2 Agonists Manufacturing Base, Sales Area and Its Competitors

Table 116. Merck Short-acting B2 Agonists Product Portfolios and Specifications

Table 117. Merck Short-acting B2 Agonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 118. Merck Main Business

Table 119. Merck Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Short-acting B2 Agonists
- Figure 2. Short-acting B2 Agonists Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Short-acting B2 Agonists Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Short-acting B2 Agonists Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Short-acting B2 Agonists Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Albuterol
- Figure 10. Product Picture of Metaproterenol
- Figure 11. Product Picture of Levalbuterol
- Figure 12. Product Picture of Other
- Figure 13. Global Short-acting B2 Agonists Sales Market Share by Type in 2022
- Figure 14. Global Short-acting B2 Agonists Revenue Market Share by Type (2018-2023)
- Figure 15. Short-acting B2 Agonists Consumed in COPD
- Figure 16. Global Short-acting B2 Agonists Market: COPD (2018-2023) & (K Units)
- Figure 17. Short-acting B2 Agonists Consumed in Asthma
- Figure 18. Global Short-acting B2 Agonists Market: Asthma (2018-2023) & (K Units)
- Figure 19. Short-acting B2 Agonists Consumed in Other
- Figure 20. Global Short-acting B2 Agonists Market: Other (2018-2023) & (K Units)
- Figure 21. Global Short-acting B2 Agonists Sales Market Share by Application (2022)
- Figure 22. Global Short-acting B2 Agonists Revenue Market Share by Application in 2022
- Figure 23. Short-acting B2 Agonists Sales Market by Company in 2022 (K Units)
- Figure 24. Global Short-acting B2 Agonists Sales Market Share by Company in 2022
- Figure 25. Short-acting B2 Agonists Revenue Market by Company in 2022 (\$ Million)
- Figure 26. Global Short-acting B2 Agonists Revenue Market Share by Company in 2022
- Figure 27. Global Short-acting B2 Agonists Sales Market Share by Geographic Region (2018-2023)
- Figure 28. Global Short-acting B2 Agonists Revenue Market Share by Geographic Region in 2022
- Figure 29. Americas Short-acting B2 Agonists Sales 2018-2023 (K Units)
- Figure 30. Americas Short-acting B2 Agonists Revenue 2018-2023 (\$ Millions)
- Figure 31. APAC Short-acting B2 Agonists Sales 2018-2023 (K Units)

- Figure 32. APAC Short-acting B2 Agonists Revenue 2018-2023 (\$ Millions)
- Figure 33. Europe Short-acting B2 Agonists Sales 2018-2023 (K Units)
- Figure 34. Europe Short-acting B2 Agonists Revenue 2018-2023 (\$ Millions)
- Figure 35. Middle East & Africa Short-acting B2 Agonists Sales 2018-2023 (K Units)
- Figure 36. Middle East & Africa Short-acting B2 Agonists Revenue 2018-2023 (\$ Millions)
- Figure 37. Americas Short-acting B2 Agonists Sales Market Share by Country in 2022
- Figure 38. Americas Short-acting B2 Agonists Revenue Market Share by Country in 2022
- Figure 39. Americas Short-acting B2 Agonists Sales Market Share by Type (2018-2023)
- Figure 40. Americas Short-acting B2 Agonists Sales Market Share by Application (2018-2023)
- Figure 41. United States Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 42. Canada Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 43. Mexico Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 44. Brazil Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 45. APAC Short-acting B2 Agonists Sales Market Share by Region in 2022
- Figure 46. APAC Short-acting B2 Agonists Revenue Market Share by Regions in 2022
- Figure 47. APAC Short-acting B2 Agonists Sales Market Share by Type (2018-2023)
- Figure 48. APAC Short-acting B2 Agonists Sales Market Share by Application (2018-2023)
- Figure 49. China Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 50. Japan Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 51. South Korea Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 52. Southeast Asia Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 53. India Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 54. Australia Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 55. China Taiwan Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 56. Europe Short-acting B2 Agonists Sales Market Share by Country in 2022
- Figure 57. Europe Short-acting B2 Agonists Revenue Market Share by Country in 2022
- Figure 58. Europe Short-acting B2 Agonists Sales Market Share by Type (2018-2023)
- Figure 59. Europe Short-acting B2 Agonists Sales Market Share by Application (2018-2023)
- Figure 60. Germany Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)
- Figure 61. France Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 62. UK Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Italy Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Russia Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Middle East & Africa Short-acting B2 Agonists Sales Market Share by Country in 2022

Figure 66. Middle East & Africa Short-acting B2 Agonists Revenue Market Share by Country in 2022

Figure 67. Middle East & Africa Short-acting B2 Agonists Sales Market Share by Type (2018-2023)

Figure 68. Middle East & Africa Short-acting B2 Agonists Sales Market Share by Application (2018-2023)

Figure 69. Egypt Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 70. South Africa Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Israel Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Turkey Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 73. GCC Country Short-acting B2 Agonists Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Manufacturing Cost Structure Analysis of Short-acting B2 Agonists in 2022

Figure 75. Manufacturing Process Analysis of Short-acting B2 Agonists

Figure 76. Industry Chain Structure of Short-acting B2 Agonists

Figure 77. Channels of Distribution

Figure 78. Global Short-acting B2 Agonists Sales Market Forecast by Region (2024-2029)

Figure 79. Global Short-acting B2 Agonists Revenue Market Share Forecast by Region (2024-2029)

Figure 80. Global Short-acting B2 Agonists Sales Market Share Forecast by Type (2024-2029)

Figure 81. Global Short-acting B2 Agonists Revenue Market Share Forecast by Type (2024-2029)

Figure 82. Global Short-acting B2 Agonists Sales Market Share Forecast by Application (2024-2029)

Figure 83. Global Short-acting B2 Agonists Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Short-acting B2 Agonists Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G8157D4BB48DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8157D4BB48DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970